Can logic-gated CAR T therapies finally crack solid tumors? A2 Biotherapeutics shares early ASCO data
A2 Biotherapeutics shares EVEREST-2 CAR T data at ASCO 2026. Find out what this means for solid tumor therapy and next-gen cell treatments.
Can Fate Therapeutics, Inc. solve the conditioning chemotherapy problem in CAR T?
Discover how FT839’s conditioning-free CAR T platform could reshape cancer and autoimmune treatment pathways. Read the full analysis now.
Why Gilead Sciences’ Arcellx acquisition reshapes the competitive dynamics of BCMA CAR T therapy
Gilead Sciences’ acquisition of Arcellx signals a strategic shift in CAR T therapy control and scale. Find out what it changes for multiple myeloma.
What CARsgen Therapeutics’ RMB370m manufacturing plan reveals about CAR-T execution risk
CARsgen Therapeutics is expanding CAR-T manufacturing in Shanghai as solid tumor programs near approval. Find out why this matters for scale and adoption.